Publications

Case Reports Journal Article Epublish

PubMed: 40529832 DOI: 10.3389/fendo.2025.1598264

Case Report: Usefulness, effectiveness, and safety of an advanced hybrid closed-loop system in a child with early identification of type 1 diabetes.

Front Endocrinol (Lausanne) 16:1598264

Authors: Chiara Mameli, Maddalena Macedoni, Francesca Redaelli, Agnese Petitti, Adelina Hajro, Alessandra Bosetti, Gianvincenzo Zuccotti

Affiliations

  • Department of Pediatrics, Vittore Buzzi Children's Hospital, Department of Biomedical and Clinical Science, Università di Milano, Milan, Italy.
  • Department of Biomedical and Clinical Sciences, "L. Sacco", Biological Chemistry and Nutritional Biochemistry Lab, Università di Milano, , Milan, Italy.

Abstract

The usefulness, effectiveness, and safety of advanced hybrid closed-loop systems (AHCLs) in early-stage 3 type 1 diabetes (T1D) are unknown. We report 9 months of continuous glucose monitoring (CGM) outcomes in a patient with early-stage 3 T1D treated with the Tandem t:slim Control-IQ ® system. A 13-year-old girl, affected by celiac disease and Hashimoto's thyroiditis, was diagnosed with T1D without symptoms (fasting c-peptide: 1.77 ng/ml; HbA1c: 6.4%) following an outpatient T1D screening program. She wore a CGM at diagnosis to closely monitor her glucose profile. After 6 months, when the time in range (TIR) fell below 80%, the Tandem t:slim Control-IQ ® was initiated. Standardized CGM metrics, as well as instances of severe hypoglycemia and diabetic ketoacidosis (DKA), were recorded. CGM data guided the initiation of early insulin therapy. Tandem t:slim Control-IQ ® system proved effective from the onset of T1D, with a low insulin requirement (0.1 U/kg/day, < 10 units/day) and maintained good metabolic control (TIR > 80%) without severe hypoglycemia or DKA. Based on our experience, we suggest a two-step approach for monitoring and treating patients with early stage 3 type 1 diabetes: first, positioning CGM, and second, when TIR falls below 80%, considering the addition of an AHCLs, even if the patient has a low insulin requirement.

MeSH

Diabetes Mellitus, Safety, Insulin, Hypoglycemia, Diabetic Ketoacidosis, Diabetes Mellitus, Type 1, Child, Endocrine System Diseases